PT  - JOURNAL ARTICLE
AU  - TURNER, MICHAEL A.
AU  - HOLLANDSWORTH, HANNAH M.
AU  - NISHINO, HIROTO
AU  - AMIRFAKHRI, SIAMAK
AU  - LWIN, THINZAR M.
AU  - LOWY, ANDREW M.
AU  - KAUR, SUKHWINDER
AU  - NATARAJAN, GOPALAKRISHNAN
AU  - MALLYA, KAVITA
AU  - HOFFMAN, ROBERT M.
AU  - BATRA, SURINDER K.
AU  - BOUVET, MICHAEL
TI  - Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft
AID  - 10.21873/invivo.12676
DP  - 2022 Jan 01
TA  - In Vivo
PG  - 57--62
VI  - 36
IP  - 1
4099  - http://iv.iiarjournals.org/content/36/1/57.short
4100  - http://iv.iiarjournals.org/content/36/1/57.full
SO  - In Vivo2022 Jan 01; 36
AB  - Background: Overexpression of mucin-5AC (MUC5AC) makes it a targetable biomarker in pancreatic cancer. The present study evaluated tumor targeting with a MUC5AC antibody conjugated to a near-infrared dye in a patient-derived orthotopic xenograft (PDOX) mouse model. Materials and Methods: MUC5AC monoclonal antibody was conjugated to the near-infrared dye IRDye800CW to synthesize MUC5AC-IR800. PDOX models were established by implanting a high-MUC5AC-expressing patient-derived pancreatic tumor on the pancreas of nude mice. After 4 weeks of PDOX tumor growth, mice were imaged after receiving MUC5AC-IR800 (75 μg) intravenously. Results: In the PDOX models, MUC5AC-IR800 selectively and brightly targeted the pancreatic tumor (tumor to background ratio: 2.46±0.465). Conclusion: MUC5AC-IR800 provides distinct visualization of pancreatic tumors. MUC5AC-IR800 may be used clinically in the future to improve pancreatic cancer resection. This novel fluorescent probe is also promising for targeting of pre-malignant pancreatic lesions with subsequent resection under fluorescence guidance.